-
There are only ten clinical studies in the world, what are the ways out for new anti-cancer drugs targeting Nectin-4?
Time of Update: 2022-11-14
● Transmembrane domain ● Cytoplasmic domain, containing an AFADIN binding module Figure 2 Nectin-4 structure Source: Nature Drug Discovery Studies have shown that in the development of tumors, Nectin-4 is associated with promoting cancer cell proliferation and metastasis by activating the Rac small G protein in the WNT-β-catenin and PI3K-AKT signaling pathways.
-
There are only ten clinical studies in the world, what are the ways out for new anti-cancer drugs targeting Nectin-4?
Time of Update: 2022-11-04
Nature Reviews Urology volume 18,pages93–103(2021) Fig. 3 Anti-tumor mechanism of action of Enfortumab vedotin Source: Nature Drug DiscoveryIn 2019, Enfortumab Vedstar (Padcev) is approved by the FDA for the treatment of locally advanced and metastatic urothelial carcinoma, becoming the first and only ADC approved for nectin-4.
-
Young brain cancer patients have been fighting cancer for 13 years, what is the credit of this targeted drug?
Time of Update: 2022-09-15
Previous treatment of brain MRI was used in July 2020 with rigofenibIn July 2020, patients began third-line therapy with rigofenib.
Previous treatment of brain MRI was used in July 2020 with rigofenibIn July 2020, patients began third-line therapy with rigofenib.
-
What to do if EGFR targeted drugs are resistant? Combination therapies are worth trying
Time of Update: 2022-09-09
Through the domestic PD-1 inhibitors sindilizumab, bevacizumab biosimilars, pemetrexed and cisplatin, it can also bring better benefits to lung cancer patients who are targeted drug-resistant.
Through the domestic PD-1 inhibitors sindilizumab, bevacizumab biosimilars, pemetrexed and cisplatin, it can also bring better benefits to lung cancer patients who are targeted drug-resistant.
-
What to do if lung cancer is resistant to targeted drugs?
Time of Update: 2022-08-20
2. MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC Post-OsimertinibClick below to learn more about clinical trialsThe problem of drug resistance of lung cancer targeted drugsIn non-small cell lung cancer, the most common driver gene mutation is EGFR mutation.
-
What are the development directions for anticancer drugs targeting Nectin-4 in more than 20 clinical studies around the world?
Time of Update: 2021-09-13
In August 2021, a new antibody-conjugated drug (ADC) targeted at Nectin-4 developed by Maiwei Biosciences recently submitted a clinical trial application in China .
-
What are the current lung cancer targeting drugs?
Time of Update: 2020-01-22
The incidence rate of incidence of lung cancer is the highest in China, accounting for about 705 thousand [1] a year Lung cancer ranks first among the incidence rate of malignancy in China's Cancer Re